Chirurgische Therapie bei peritonealen Metastasen gynäkologischer Primärtumoren

Dragos Horvath,Prof. Dr. A. Königsrainer

Published 2018 in Der Chirurg

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2018
Venue
Der Chirurg
Publication date
2018-07-05
Fields of study
Not labeled
Identifiers
DOI 10.1007/s00104-018-0679-1
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
2018cited by this paper
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018cited by this paper
Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO DESKTOP III/ENGOT ov20
2017cited by this paper
The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
2017cited by this paper
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
2016cited by this paper
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database
2016cited by this paper
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
2016cited by this paper
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
2015cited by this paper
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
2015cited by this paper
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
2015cited by this paper
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience
2014cited by this paper
HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum‐based chemotherapy in patients with platinum‐sensitive recurrent epithelial ovarian cancer
2014cited by this paper
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi‐institutional study
2012cited by this paper
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
2012cited by this paper
Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
2012cited by this paper
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012cited by this paper
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients
2012cited by this paper
Ovarian cancer: diagnosis and treatment.
2011cited by this paper
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
2009cited by this paper
Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis
2009cited by this paper
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
2009cited by this paper
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer
2008cited by this paper
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
2008cited by this paper
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
2007cited by this paper
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients
2007cited by this paper
Peritoneal metastasiertes Ovarialkarzinom
2007cited by this paper
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
2007cited by this paper
Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
2007cited by this paper
[Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].
2007cited by this paper
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2007cited by this paper
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
2006cited by this paper
Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma
2005cited by this paper
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer
2004cited by this paper
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
2004cited by this paper
NEOADJUVANT CHEMOTHERAPY VERSUS PRIMARY DEBULKING SURGERY IN ADVANCED OVARIAN CANCER
2003cited by this paper
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
2002cited by this paper
Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer
2001cited by this paper
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr
2001cited by this paper
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
2001cited by this paper
Treatment of advanced ovarian cancer in Germany. Survey results from the Organkommission OVAR of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) of the German Cancer Association
2001cited by this paper
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
2000cited by this paper
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer
2000cited by this paper
CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER
2000cited by this paper
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
1996cited by this paper
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
1996cited by this paper
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
1993cited by this paper

CITED BY

No citing papers are available for this paper.